Abstract: A method and apparatus for controlling learning of a model for estimating an intention of an input utterance is disclosed. A method of controlling learning of a model for estimating an intention of an input utterance among a plurality of intentions includes providing a first index corresponding to the number of registered utterances for each intention, providing a second index corresponding to a learning level for each intention, providing a learning target setting interface such that at least one intention that is to be a learning target is selected from among the intentions based on the first index and the second index, and training the model based on the registered utterances for each intention and setting of the learning target for each intention.

Abstract: The present invention relates to a polycyclic aromatic derivative compound that can be used in a variety of organic material layers in an organic light-emitting element, and an organic light-emitting element comprising the polycyclic aromatic derivative compound, the highly efficient and long-life organic light-emitting element having significantly improved light-emitting efficiency by employing the polycyclic aromatic compound as a dopant compound in a light-emitting layer, and an anthracene derivative having a particular structure as a host compound.

Abstract: According to an embodiment of the present disclosure, a memory device for a logic-in-memory may include a cell array including a plurality of ternary memory cells, a row decoder configured to select at least one ternary memory cell from among the plurality of ternary memory cells, and a page buffer configured to provide a first value to the at least one ternary memory cell and latch a third value obtained by performing a logic operation on the first value and a second value stored in the at least one ternary memory cell and/or the second value.

Abstract: Disclosed are a particle-attached microneedle having a solid-phase drug mounted thereon, and a method of manufacturing the particle-attached microneedle. More particularly, the particle-attached microneedle includes a microneedle (10), an adhesive layer (11), solid-phase drug particles (22), a film (21), and a coating well (20).

Abstract: The present invention relates to a composition for ameliorating, preventing or treating alopecia, comprising a catechin 7-O-?-D-apiofuranoside compound as an active ingredient. The compound of the present invention inhibits the production of dihydrotestosterone (DHT) converted from testosterone by 5-alpha-reductase in human-derived dermal papilla cells, and inhibits the apoptosis induced by oxidative stress in dermal papilla cells, and accordingly, can be used as an active ingredient for the treatment, prevention, or amelioration purposes.

Abstract: The present invention relates to a heteroaryl derivative and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient, and a compound according to an aspect of the present invention, a stereoisomer thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof suppresses kinases, particularly, a TTK kinase, and thus can remarkably suppress the proliferation of cancer cells, and accordingly, can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer.

Abstract: A polycyclic aromatic compound or a condensed multimer thereof, according to the present invention, is employed in an organic layer in an organoelectroluminescent device, thereby enabling the implementation of an organoelectroluminescent device having high efficiency and a long lifespan, and thus the present invention may be industrially useful in various display devices such as a flat panel display device, a flexible display device, a monochromatic or white flat panel lighting device, and a monochromatic or white flexible lighting device.

Abstract: Methods and apparatuses are described herein for enhancing performance of a user. For example, an apparatus may generate one or more performance enhancing instructions that cause, based on the user's performance of the performance enhancing instructions, at least one physiological changes in the user's physiological mechanism to cope with at least one of anxiety or stress. The at least one physiological changes may include at least one of dopamine secretion induction, oxytocin secretion induction, cortisol level reduction, melatonin secretion induction, or synapsing promotion. The apparatus may then provide the user the one or more performance enhancing instructions via the apparatus. The one or more performance enhancing instructions may comprise a first/second concentration enhancing digital instruction, an anxiety/stress reducing digital instruction, and a coordination & agility enhancing digital instruction.

Abstract: The present invention relates to a polycyclic aromatic derivative compound and an organic light-emitting device having high efficiency and long lifespan, the device applying the compound in various organic layers so as to remarkably improve luminous efficiency. According to the invention, an organic light-emitting device having high efficiency and long lifespan and having remarkably improved luminous efficiency can be implemented, and thus can be industrially useful in various display devices and lighting devices.

Abstract: The present invention relates to a polycyclic aromatic derivative compound that can be employed in an organic layer in a device, and an organoelectroluminescent device with high-efficiency and a long-life, including same and having remarkably improved luminous efficiency, and the device employing same can be efficiently utilized in a variety of displays and lighting devices, such as a flat panel display device, a flexible display device, a single color or white flat lighting device, and a single color or white flexible lighting device.

Abstract: Disclosed is a composition for preventing or treating a degenerative brain disease. The composition includes, as an active ingredient, a MECP2 inhibitor for treating the degenerative brain disease, a polynucleotide encoding the MECP2 inhibitor or a recombinant virus containing the MECP2 inhibitor. The composition is useful for the treatment of a degenerative brain disease (particularly Alzheimer's syndrome) caused by beta-amyloid. In addition, the composition is effective in improving or ameliorating deterioration of cognitive functions and social deficits caused by Alzheimer's syndrome.

Abstract: According to the present embodiments, it is possible to enhance the driver's steering feel by limiting the maximum steering angle of the steering wheel and easily change the maximum steering angle of the steering wheel in real-time or with a minimum structure change as necessary.

Abstract: Disclosed is a polycyclic compound that can be employed in various organic layers of an organic electroluminescent device. Also disclosed is an organic electroluminescent device including the polycyclic compound. The organic electroluminescent device includes a light emitting layer employing the polycyclic compound as a dopant and an anthracene derivative having a characteristic structure and characteristic substituents as a host. The use of the polycyclic compound significantly improves the color purity, luminous efficiency, and life characteristics of the organic electroluminescent device and makes the organic electroluminescent device highly efficient and long lasting.

Abstract: The present invention relates to a novel polycyclic compound employed in an organic layer of an organoelectro luminescent device, wherein the organoelectro luminescent device employing the compound according to the present invention has remarkably improved luminous efficiency. According to the present invention, it is possible to implement a highly efficient organoelectro luminescent device that can be effectively applied to various display devices.

Abstract: An autonomous vehicle, a control system for remotely controlling the same, and a method thereof may include an autonomous driving control apparatus including a processor for determining whether remote control of the autonomous vehicle is required according to at least one of occurrence of failure of the vehicle during autonomous driving thereof, occurrence of an accident, a region where the autonomous driving is not possible, reliability of positioning data of the vehicle, a stopping time of the vehicle, or a response point of a hand signal, and for requesting the remote control to a control system when the remote control of the vehicle is required.

Abstract: An autonomous vehicle may include an autonomous driving control apparatus having a processor that transmits vehicle data and a vehicle path for remote control of the autonomous vehicle to a control system when the remote control of the autonomous vehicle is required, and performs following and control based on adjusted path information when receiving the adjusted path information from the control system.

Abstract: An autonomous vehicle may include a processor configured to transmit vehicle data for remote control of the autonomous vehicle to a control system when the remote control of the autonomous vehicle is required, and when receiving a remote control command for the remote control from the control system, to generate and follow a path based on the received remote control command.

Abstract: A method for generating treatment regimen for one or more health conditions includes retrieving a stored healthcare treatment model that has been trained to identify, for each of a plurality of health conditions, one or more respective treatment programs. Each of the treatment programs includes a respective treatment user interface to modify a respective behavior associated with one or more neurohumoral factors that are associated with the respective health condition. In response to receiving input that specifies a first health condition of the one or more health conditions, the method uses the healthcare treatment model to select one or more treatment programs corresponding to the first health condition and provides the treatment user interfaces for the one or more treatment programs.

Abstract: A memory system includes a first memory device including a plurality of first physical blocks; a second memory device including a plurality of second physical blocks; a first core suitable for managing a plurality of first super blocks that store data associated with a first logical address, the plurality of first super blocks being mapped to the plurality of first physical blocks; a second core suitable for managing a plurality of second super blocks that store data associated with a second logical address, the plurality of second super blocks being mapped to the plurality of second physical blocks; a global wear-leveling manager suitable for changing mapping between the first physical blocks, which are mapped to one among the first super blocks, and the second physical blocks, which are mapped to one among the second super blocks based on degrees of wear of the first and second super blocks.

Abstract: Disclosed is a polycyclic compound that can be employed in various organic layers of an organic electroluminescent device. The polycyclic compound has a characteristic skeleton structure and characteristic substituents. Also disclosed is an organic electroluminescent device including the polycyclic compound. The organic electroluminescent device includes a light emitting layer employing the polycyclic compound as a dopant and an anthracene derivative having a characteristic structure as a host. The use of the polycyclic compound significantly improves the luminous efficiency and life characteristics of the organic electroluminescent device and makes the organic electroluminescent device highly efficient and long lasting.